Hereditary Hemochromatosis

Nanogen expands genetic content patent portfolio

Published in Blood Weekly, July 18th, 2002

Nanogen, Inc., (NGEN) announced the issuance of U.S. Patent No. 6,355,425 (the '425 patent) entitled "Mutations Associated with Iron Disorders" relating to methods for the detection of certain mutations linked to hereditary hemochromatosis (HH).

HH is a genetically inherited disease that results in excess storage of iron, principally in the liver and bone joints. Nanogen has had an exclusive license to the '425 patent from Billups-Rothenberg, Inc., and Dr. Barry E. Rothenberg since 1998.

The '425 patent addresses identification and detection of mutations in the HFE gene, which is critical to diagnosing HH. Under this patent, Nanogen has exclusive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-07-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry